- Home
- PRME vs EYPT Comparison
PRME vs EYPT Comparison
Compare PRME & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- EYPT
- Stock Information
- Founded
- PRME 2019
- EYPT 1987
- Country
- PRME United States
- EYPT United States
- Employees
- PRME N/A
- EYPT N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- PRME Health Care
- EYPT Industrials
- Exchange
- PRME Nasdaq
- EYPT Nasdaq
- Market Cap
- PRME 424.9M
- EYPT 439.4M
- IPO Year
- PRME 2022
- EYPT 2005
- Fundamental
- Price
- PRME $4.10
- EYPT $11.63
- Analyst Decision
- PRME Strong Buy
- EYPT Strong Buy
- Analyst Count
- PRME 8
- EYPT 8
- Target Price
- PRME $14.14
- EYPT $27.71
- AVG Volume (30 Days)
- PRME 927.9K
- EYPT 1.1M
- Earning Date
- PRME 11-19-2024
- EYPT 11-07-2024
- Dividend Yield
- PRME N/A
- EYPT N/A
- EPS Growth
- PRME N/A
- EYPT N/A
- EPS
- PRME N/A
- EYPT N/A
- Revenue
- PRME $591,000.00
- EYPT $45,713,000.00
- Revenue This Year
- PRME N/A
- EYPT N/A
- Revenue Next Year
- PRME N/A
- EYPT N/A
- P/E Ratio
- PRME N/A
- EYPT N/A
- Revenue Growth
- PRME N/A
- EYPT 7.50
- 52 Week Low
- PRME $3.28
- EYPT $5.86
- 52 Week High
- PRME $9.86
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- PRME 52.64
- EYPT 59.38
- Support Level
- PRME $3.85
- EYPT $11.06
- Resistance Level
- PRME $4.20
- EYPT $12.50
- Average True Range (ATR)
- PRME 0.29
- EYPT 1.10
- MACD
- PRME -0.00
- EYPT 0.01
- Stochastic Oscillator
- PRME 42.42
- EYPT 50.42
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.